Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 1/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 1/20 | 1.00 |
| ▸ | GABRE | P78334 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicuculline SCHEMBL28213750 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL16320040 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29617593 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29390611 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL8222 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5481014 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29366341 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL7913545 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5783586 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL2532354 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | claimed |
| US-20250281474-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | UNIVERSITY OF THE RYUKYUS (JP) | 2025-09-11 | — | — | US | disclosed |
| CN-119490455-A | Refining method of sinomenine hydrochloride for injection | 湖南知著科技有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240398775-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE OR FOR USE IN TREATING OVERWEIGHT OR OBESITY | UNIVERSITY OF THE RYUKYUS (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4403185-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | University of The Ryukyus (JP) | 2024-07-24 | — | — | EP | disclosed |
| EP-4403184-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE, EXCESS WEIGHT, OR OBESITY | University of The Ryukyus (JP) | 2024-07-24 | — | — | EP | disclosed |
| CN-118130652-A | Analysis method of sinomenine hydrochloride related substances | 湖南正清制药集团股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240075004-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-07 | — | — | US | disclosed |
| CN-117630239-A | Method for detecting related substances in sinomenine hydrochloride | 湖南知著科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116235853-A | Plant growth regulator and application thereof in promoting plant growth, increasing plant yield and enhancing plant stress resistance | 中国农业大学 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023042888-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | 国立大学法人 琉球大学 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023042887-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE, EXCESS WEIGHT, OR OBESITY | 国立大学法人 琉球大学 | 2023-03-23 | — | — | WO | disclosed |
| CN-109180776-B | Removal of serine proteases by treatment with finely divided silica | 武田药品工业株式会社 | 2022-12-13 | — | — | CN | disclosed |
| US-20220339134-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-10-27 | — | — | US | disclosed |
| EP-4025201-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022140418-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114561277-A | Methods and devices for conditioning cell populations for cell therapy | 得克萨斯州大学系统董事会 | 2022-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339134-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | ELOVL3, ELOVL1, ALOX5 | CYP3A4 1462/4885CYP2C9 2949/4885CYP2C19 1848/4885 |
| US-20240075004-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | ELOVL3, ELOVL1, ALOX5 | CYP3A4 1462/4885CYP2C9 2949/4885CYP2C19 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.